Telix completes 350-patient Phase 3 BiPASS trial enrollment for PSMA-PET before prostate biopsy
Telix has completed enrollment of 350 patients in the Phase 3 BiPASS study testing Illuccix and Gozellix PSMA-PET with MRI before prostate biopsy and has aligned with the FDA on an NDA pathway.